Notícias

Categoria:

Cerimónia de entrega de prémios da 10ª Edição do Prémio Empreendedorismo e Inovação Crédito Agrícola

Realiza-se no próximo dia 28 de novembro a Cerimónia de Entrega de Prémios da 10ª...

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

– Zilebesiran Met Primary Endpoint Demonstrating Up to 16.7 mmHg Placebo-Adjusted Reduction of 24-Hour Mean...

P-BIO participa na Conferência Anual da International Platform of Insects for Food and Feed

A P-BIO esteve presente nos passados dias 14 e 15 deste mês na Conferência Anual...

Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

P-BIO October 15, 2023 - cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening...

Simão Soares – President, P-BIO

Imagem: P-BIO P-BIO 15 de outubro de 2023 P-BIO, Portugal’s leading association for its biotech...

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

P-BIOOctober 15,  2023- FRUZAQLA is the First Targeted Therapy Approved for Metastatic Colorectal Cancer (mCRC)...